Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

SpainBack to Spain

Clinical trials in Malaga – page 67

1 052 clinical trials in Malaga, Spain across 4 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

SpainOur site in SpainEnsayosClinicos.es(opens in a new tab)
Malaga at a glance
1 052
clinical trials
  • Research sites4
Type of trial
Recruitment status
Quick filters

1 052 trials in Malaga

Open in trial search

Small cell lung cancer extensive stage

Not recruiting

Study of Pembrolizumab, Lenvatinib, and Chemotherapy for First-Line Treatment in Extensive-Stage Small Cell Lung Cancer Patients

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Lenvatinib
  • Sponsor:Fundacion GECP

Neoplasm

Not recruiting

Study of BMS-986253 with Nivolumab and Ipilimumab for Patients with Advanced Solid Tumors

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Ipilimumab
  • Sponsor:Bristol Myers Squibb International Corporation

Hypertrophic cardiomyopathy

Not recruiting

Study on the Effects of MYK-224 for Patients with Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Bms-986435
  • Sponsor:Myokardia Inc.

Squamous cell carcinoma of lung

Not recruiting

Study of Pembrolizumab, Carboplatin, and Paclitaxel for Patients with Metastatic Squamous Non-small Cell Lung Cancer

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Merck Sharp & Dohme LLC

Non-small cell lung cancer+1

Not recruiting

Study of Chemotherapy and Nivolumab Before and After Surgery for Patients with Non-Small Cell Lung Cancer in the Upper Lung Area

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Fundacion GECP

HIV infection

Not recruiting

Study on HIV-1 Treatment for Patients New to Therapy: Comparing Doravirine/Islatravir with a Drug Combination

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Bictegravir
  • Sponsor:Merck Sharp & Dohme LLC

Essential thrombocythaemia

Not recruiting

Study on Bomedemstat for Patients with Essential Thrombocythemia Not Responding to or Intolerant of Hydroxyurea, Comparing with a Drug Combination

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Bomedemstat
  • Sponsor:Merck Sharp & Dohme LLC

Type 2 diabetes mellitus

Not recruiting

Study on the Effects of Switching from Daily Basal Insulin to Weekly Insulin Icodec Compared to Daily Insulin Glargine in Adults with Type 2 Diabetes

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Insulin Glargine
  • Sponsor:Novo Nordisk A/S

Prostate cancer metastatic

Not recruiting

Study of Niraparib, Abiraterone Acetate, and Prednisone for Patients with Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone
  • Sponsor:Janssen Cilag International

Prostate cancer metastatic

Not recruiting

Study of Niraparib, Abiraterone Acetate, and Prednisone for Patients with Metastatic Prostate Cancer

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone
  • Sponsor:Janssen Cilag International

Hormone receptor positive breast cancer+2

Not recruiting

Study of palbociclib with hormone therapy versus hormone therapy alone in patients with recurrent hormone receptor-positive/HER2-negative breast cancer after surgery

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Palbociclib
  • Sponsor:ETOP IBCSG Partners Foundation

Immune thrombocytopenia

Not recruiting

Study on the Safety and Effectiveness of Rilzabrutinib for Adults and Adolescents with Persistent or Chronic Immune Thrombocytopenia (ITP)

Investigational
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Rilzabrutinib
  • Sponsor:Principia Biopharma Inc.

Other cities in Spain

The busiest research cities in the country

All 218 cities in Spain

Clinical research in Malaga

What the registry says about research in the country

01 Autoimmune Conditions

Research focusing on innovative treatments for cutaneous lupus erythematosus and myasthenia gravis, evaluating new therapeutic approaches to improve patient outcomes.

  • Lupus skin manifestations
  • Neuromuscular disorders
  • Chronic urticaria management

Studies aim to assess novel therapies' effectiveness in reducing disease activity and improving daily living activities.

02 Infectious Diseases

Innovative vaccine development studies targeting COVID-19, cytomegalovirus, and respiratory syncytial virus, focusing on prevention and immune response.

  • Viral infections
  • Vaccine combinations
  • Pediatric prevention

Research emphasizes safety and immunogenicity in various population groups.

03 Oncology

Advanced studies in bladder cancer, colorectal cancer, and gastric cancer, evaluating targeted therapies and combination treatments.

  • Non-muscle invasive treatments
  • Metastatic disease management
  • Immunotherapy approaches

Trials focus on improving survival rates and treatment responses in various cancer types.

04 Respiratory Medicine

Research examining new treatments for chronic rhinosinusitis and COPD, with emphasis on symptom management and exacerbation prevention.

  • Airway inflammation
  • Pulmonary function
  • Quality of life measures

Studies evaluate novel therapeutic approaches for chronic respiratory conditions.

Back to SpainAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.